IDbyDNA Participates in NIH National COVID-19 Genomics Consortium
May 7, 2020
The CDC is leading the national SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance initiative (SPHERES) to coordinate SARS-CoV-2 sequencing across the U.S. Utah’s own IDbyDNA will be participating in the effort along with clinical and public health laboratories, academic institutions, and other private sector companies. The SPHERES consortium aims to generate information about the virus that will strengthen COVID-19 mitigation strategies.
In addition to IDbyDNA, corporate participants include Abbott Diagnostics, BioMérieux, Color, Ginkgo Bioworks, Illumina, In-Q-Tel, LabCorp, One Codex, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Quest Diagnostics, and Verily Life Sciences.
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
